Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Shares Outstanding (Weighted Average): 2021-2025

Historic Shares Outstanding (Weighted Average) for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $2.4 million.

  • InMed Pharmaceuticals' Shares Outstanding (Weighted Average) rose 257.44% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 257.44%. This contributed to the annual value of $1.2 million for FY2025, which is 188.87% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Shares Outstanding (Weighted Average) of $2.4 million as of Q3 2025, which was up 97.50% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $2.4 million during Q3 2025, and registered a low of $18,754 during Q3 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $696,939, with a median of $417,898 in 2024.
  • Data for InMed Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 488.56% (in 2023) over the last 5 years.
  • InMed Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $28,274 in 2021, then spiked by 65.66% to $46,838 in 2022, then soared by 460.97% to $262,748 in 2023, then soared by 173.28% to $718,032 in 2024, then skyrocketed by 257.44% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $1.2 million for Q2 2025, and $1.2 million during Q1 2025.